Patheon to Showcase Biologics Services at BIO International Convention

Patheon now offers access to alternative financing of biopharmaceutical product development through its new facility in Brisbane, Australia

Patheon, a business unit of DPx Holdings B.V., will be exhibiting and showcasing their biological service offerings at the BIO International Convention in San Diego, Calif., between June 23-26.

This past March, DPx Holdings B.V. emerged as a result of a $2.6 billion deal between Patheon and Royal DSM’s Pharmaceutical Products business. The result was the first contract development and manufacturing organization (CDMO) to offer end-to-end services. More specifically, the company now delivers the full spectrum of development and manufacturing services ranging from active pharmaceutical ingredients (API), whether for small molecule or biologics, to development services and commercial-scale manufacturing.

Dr. Manja Bouman, President, Biologics and BioSolutions, Patheon, shared, “We understand our clients’ challenges to develop and manufacture biological drugs and also the challenges of our biotech customers to finance their research and development programs, and we are constantly looking for ways to help address these issues. By opening our mammalian cGMP production facility in Brisbane, Australia, in 2013, we now offer our customers a state-of-the-art, full disposable drug substance manufacturing facility in addition to the sterile fill-finish capabilities in Monza and Ferentino, Italy, and Greenville, N.C., USA.”

Bouman goes on to highlight, “The facility in Brisbane also provides the ability for companies to apply for a 45 percent cash rebate program through the Australian Tax Office for eligible R&D programs including development and manufacturing work and clinical trial studies. To be eligible for this rebate program, minimally 50 percent of the development program needs to be performed in Australia. The financial benefit to biotech customers that the Australian government offers in combination with manufacturing at Patheon Brisbane is significant and provides an alternative way to help finance biotech companies.”

In addition to the R&D tax rebate program offered by the Australian Government, clients of Patheon can also benefit from the AUD 2 million Access Support Grants provided by partner organization, BioPharmaceuticals Australia. As part of their major efforts to develop Queensland’s biotech industry, BioPharmaceuticals Australia supports biopharmaceutical companies who decide to develop, scale-up and manufacture with Patheon in Australia. BioPharmaceuticals Australia will manage and fund the tax-rebate application and obligations for non-Australian biotech customers. 

“BioPharmaceuticals Australia is committed to supporting endeavors to build the client pipeline in the new facility,” said David Hughes, CEO BPA. “We foresee Patheon biologic capabilities and services investment locally as a key contributor to a thriving biotech cluster based upon Australia’s advantages for accelerated clinical development.”

In addition, in June Patheon cGMP facility in Brisbane was awarded the ISPE 2014 Facility of the Year Award for Process Innovation. This state-of-the-art facility offers mammalian cell culture-based contract manufacturing services from pre-clinical to commercial supply.

Patheon executives as well as technical and scientific experts will attend the BIO International Convention and will be available to discuss the biologic services, the Brisbane cGMP facility and the R&D tax rebate program. Representatives from Patheon can be found at Booth #1427 and from BPA at Booth #1925 for the duration of the conference. To schedule a meeting in advance, please email media@patheon.com.

For more information on upcoming events, visit http://www.patheon.com/Knowledge-Library/Events.aspx.

DPx Holdings B.V. Media Relations
Tel: +1 (919) 226-3200
Email: media@patheon.com

About DPx Holdings B.V.
DPx Holdings B.V. is the privately held parent company of the Patheon, DSM Fine Chemicals and Banner Life Sciences businesses.  The company is a leading provider of CDMO services, pharmaceutical products and products for other industries. DPx Holdings B.V. was founded in 2014 as a result of a deal between JLL Partners and Royal DSM. With a global headquarters in Durham, N.C., DPx Holdings B.V. has a footprint of more than 20 locations across North America, Europe, Latin America and Australia with more than 8,000 employees. DPx Holdings B.V. offers customers unsurpassed quality, integrated offerings and value through these three business units. For more information visit www.patheon.com/DPx.

About Patheon
Patheon is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Patheon, a DPx Holdings B.V. business unit, encompasses the combined CMO capabilities and pharmaceutical product development services (PDS), as well as the Biosolutions and Biologics (BIO) business. For more information visit www.patheon.com.